Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...
Neuroscience imaging company IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) has presented new research at a European conference ...
Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...
Angels on Call Homecare has successfully achieved Certified Parkinson's Disease Care (CPDC) re-accreditation through PMD Alliance for the second time, reinforcing the organization's national ...
Doctors say clinical trials are needed to understand more after Ed Patrick identified a potential side effect of a ...
In the Phase 3 TEMPO program, AbbVie’s Juvmo elicited significant improvements in motor symptoms and prolonged periods with ...
MedPage Today on MSN
Parkinson's disease gets new treatment approved
FDA gives go-ahead to D1/D5 dopamine agonist tavapadon ...
Four presentations highlight significant treatment gaps in isolated dystonia and new research providing mechanistic rationale for targeting muscarinic cholinergic receptors for treating movement ...
Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.
Better understanding of Parkinson’s removes the mystery. Here are five points to provide clarity, prompt action and give hope ...
7h
AskBio’s bold ambition to help people with Parkinson’s disease look forward — and maybe even tango
"Among the aims of the research team is to better understand whether gene therapy may one day provide a different approach to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results